David Meeker, M.D.

David Meeker, M.D.
Chair of the Board, President and CEO of Rhythm Pharmaceuticals

David Meeker, M.D., currently serves as the President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM). Prior to joining Rhythm Pharmaceuticals, Dr. Meeker served as President and Chief Executive Officer of KSQ Therapeutics, Inc. from 2017 to 2020. Prior to joining KSQ, Dr. Meeker worked at Sanofi Genzyme from 2011 to 2017, in a variety of roles, including as President and Chief Executive Officer of Genzyme, a Sanofi Company, as a member of Sanofi’s Executive Committee, and as Executive Vice President and Head of Sanofi Genzyme, Sanofi’s specialty care unit with responsibility for rare diseases, multiple sclerosis, oncology and immunology franchises. Prior to joining Genzyme, Dr. Meeker was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic Dr. Meeker has served as a Director of Rhythm Pharmaceuticals, Inc. since November 2015 and as its Chairman since April 2017. Dr. Meeker has served as Chair of Trevi Therapeutics since 2017.  He also served as a Director of MyoKardia, Inc. until their acquisition by Bristol Myers Squibb. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000.